Pfizer Reports Results of Lyrica (pregabalin) in P-III Study for Primary Generalized Tonic-Clonic Seizures
Shots:
- The P-III study involves assessing of Lyrica (pregabalin- bid- 5mg/10mg) vs PBO in 219 patients in a ratio (1:1:1) with PGTC seizures aged 5 to 65 yrs. across 21 countries for 12wks.
- The P-III study results demonstrated that it did not meet its 1EPs i.e- reduction in seizure frequency
- Lyrica (pregabalin) is a chemical analog of Gabapentin and is an approved therapy for multiple indications for both adults & pediatric patients across 130 countries including the US
Ref: Pfizer | Image: Total Ventures
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com